Our translational research group develops and applies mass spectrometry (MS) based proteomics workflows for spatially-resolved systems biology. For this purpose, we use a combination of analytical tools including multi-level proteomics (expression-, interaction- phospho-proteomics) and functional cell biology assays.
We have recently co-developed , a first-of-its-kind concept that combines high-resolution imaging, AI-guided image analysis and ultra-sensitive MS-based proteomics. Applied to preclinical models and archived biobank specimens, this concept allows us to gain unprecedented insights into cellular proteome heterogeneity.
As part of the Berlin-centered Research Node ‘’ (Multimodal clinical mass spectrometry to target treatment resistance), our MDC group closely collaborates with the Berlin Institute of Health, the Max Planck Institute for Molecular Genetics and the Humboldt University and the CHARITÉ. MSTARS, which is funded by the German Ministry of Science and Technology (BMBF) combines a broad range of complementary proteomic, metabolomic and imaging-based technologies with computational approaches for next-level patient care.
Our long-term vision is to decipher molecular and cellular disease pattern that can be used as predictive measures in precision oncology.
From left to right: Di Qin, Jeannine Engel, Fabian Coscia, Janett König, Anuar Makhmut, Jose Nimo, Sonja Fritzsche
- June 2021: Principal Investigator ‘Spatial Proteomics Group’
Max Delbrück Center for Molecular Medicine, Berlin, Germany.
- 2017-2021: Post-Doc, Mann lab (Clinical Proteomics)
University of Copenhagen (NNF Center for Protein Research)
From 2019: Marie Skłodowska-Curie Postdoctoral Fellow
- 2012- 2016: PhD candidate (Dr. rer. nat.), Mann lab
Max Planck Institute of Biochemistry, Munich, Germany
- 2009-2011: Master of Science Molecular Biotechnology
TUM Munich, Germany.